摘要
卫生技术评估越来越多地被用于健康产品的价值评估并决定资源如何最大化利用。文章详细介绍了德国专利药价格管理历程、AMONG法案的主要内容及AMONG法案下早期效益评估与价格协商谈判的关键要点,为我国创新药医保目录准入与动态调整决策中应用卫生技术评估提供参考。
Health technology assessments are increasingly used to evaluate the value of health products and determine how to maximize the use of resources.It introduces the history of German patent drug price management,the main content of the AMONG act,and the key points concerning early benefit assessment and price negotiation under the AMONG act,so as to provide references for the application of health technology assessment in national medical insurance directory access and dynamic adjustment decisions.
作者
蒋蓉
谢金平
邵蓉
JIANG Rong;XIE Jin-ping;SHAO Rong(The Research Center of National Drug Policy&Ecosystem,China Pharmaceutical University,Nanjing,211198,China)
出处
《中国卫生经济》
北大核心
2021年第5期92-96,共5页
Chinese Health Economics
基金
2015年度国家社科基金重大项目(15ZDB167)。
关键词
早期效益评估
卫生技术评估
价格谈判
国家医保目录
德国
early benefit assessment
health technology assessment
price negotiation
National Medical Insurance Catalogue
Germany